{"transactions":[{"id":2482660,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T21:30:32.000Z","date":"2021-12-03","kind":"other","acquired":false,"shares":24172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."}],"balance_after":1261,"source":{"system":"sec-edgar","filing":"0000899243-21-047117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321047117/doc4.xml","form_type":"4"}},{"id":2482659,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T21:30:32.000Z","date":"2021-12-03","kind":"other","acquired":false,"shares":49730,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities were held by Co-Investment IV."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-047117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321047117/doc4.xml","form_type":"4"}},{"id":2482658,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-07T21:30:32.000Z","date":"2021-12-03","kind":"other","acquired":false,"shares":750270,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Fund IV."}],"balance_after":1510521,"source":{"system":"sec-edgar","filing":"0000899243-21-047117","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924321047117/doc4.xml","form_type":"4"}},{"id":2534463,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2021-10-26T17:02:14.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":1437297,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":151294},"source":{"system":"sec-edgar","filing":"0001104659-21-130027","document":"tm2130646-25_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000110465921130027/tm2130646-25_4seq1.xml","form_type":"4"}},{"id":2534462,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-10-26T17:02:14.000Z","date":"2021-10-26","kind":"exercise","acquired":false,"shares":6324110,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":665696},"source":{"system":"sec-edgar","filing":"0001104659-21-130027","document":"tm2130646-25_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000110465921130027/tm2130646-25_4seq1.xml","form_type":"4"}},{"id":2534461,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T17:02:14.000Z","date":"2021-10-26","kind":"purchase","acquired":true,"shares":312500,"price":16,"value":5000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":1129490,"source":{"system":"sec-edgar","filing":"0001104659-21-130027","document":"tm2130646-25_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000110465921130027/tm2130646-25_4seq1.xml","form_type":"4"}},{"id":2534460,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T17:02:14.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":151294,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":816990,"source":{"system":"sec-edgar","filing":"0001104659-21-130027","document":"tm2130646-25_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000110465921130027/tm2130646-25_4seq1.xml","form_type":"4"}},{"id":2534459,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-10-26T17:02:14.000Z","date":"2021-10-26","kind":"exercise","acquired":true,"shares":665696,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":665696,"source":{"system":"sec-edgar","filing":"0001104659-21-130027","document":"tm2130646-25_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000110465921130027/tm2130646-25_4seq1.xml","form_type":"4"}},{"id":2963110,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-02T02:36:43.000Z","date":"2020-12-01","kind":"other","acquired":false,"shares":43537,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a transfer, without the payment of any consideration, to an affiliate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents a transfer, without the payment of any consideration, to an affiliate."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Includes 2,260,791 shares of common stock held by Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and 49,730 shares of common stock held by Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\"). Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Fund IV and Co-Investment IV are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."}],"balance_after":2310521,"source":{"system":"sec-edgar","filing":"0000899243-20-032411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320032411/doc4.xml","form_type":"4"}},{"id":3037879,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-05T01:09:21.000Z","date":"2020-09-04","kind":"other","acquired":false,"shares":45460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."}],"balance_after":43537,"source":{"system":"sec-edgar","filing":"0000899243-20-024411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320024411/doc4.xml","form_type":"4"}},{"id":3037878,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-05T01:09:21.000Z","date":"2020-09-04","kind":"other","acquired":false,"shares":31650,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Co-Investment IV."}],"balance_after":49730,"source":{"system":"sec-edgar","filing":"0000899243-20-024411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320024411/doc4.xml","form_type":"4"}},{"id":3037877,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-09-05T01:09:21.000Z","date":"2020-09-04","kind":"other","acquired":false,"shares":1468350,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Fund IV."}],"balance_after":2260791,"source":{"system":"sec-edgar","filing":"0000899243-20-024411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320024411/doc4.xml","form_type":"4"}},{"id":3052622,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-19T23:40:59.000Z","date":"2020-08-19","kind":"sale","acquired":false,"shares":7303,"price":107.64,"value":786094.92,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."}],"balance_after":42875,"source":{"system":"sec-edgar","filing":"0000899243-20-022972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320022972/doc4.xml","form_type":"4"}},{"id":3052621,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-19T23:40:59.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":10197,"price":110.03,"value":1121975.91,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."}],"balance_after":50178,"source":{"system":"sec-edgar","filing":"0000899243-20-022972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320022972/doc4.xml","form_type":"4"}},{"id":3052620,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-19T23:40:59.000Z","date":"2020-08-17","kind":"sale","acquired":false,"shares":12500,"price":110.73,"value":1384125.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."}],"balance_after":60375,"source":{"system":"sec-edgar","filing":"0000899243-20-022972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320022972/doc4.xml","form_type":"4"}},{"id":3130872,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:51:16.000Z","date":"2020-05-27","kind":"other","acquired":false,"shares":44903,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."}],"balance_after":72875,"source":{"system":"sec-edgar","filing":"0000899243-20-014567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320014567/doc4.xml","form_type":"4"}},{"id":3130871,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:51:16.000Z","date":"2020-05-27","kind":"other","acquired":false,"shares":6772,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Co-Investment IV."}],"balance_after":81380,"source":{"system":"sec-edgar","filing":"0000899243-20-014567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320014567/doc4.xml","form_type":"4"}},{"id":3130870,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:51:16.000Z","date":"2020-05-27","kind":"other","acquired":false,"shares":360561,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F4","text":"Represents transfers, without the payment of any consideration, to their partners and employees."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Fund IV."}],"balance_after":3729141,"source":{"system":"sec-edgar","filing":"0000899243-20-014567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924320014567/doc4.xml","form_type":"4"}},{"id":3208920,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":15457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in three equal installments on March 16, 2021, 2022 and 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"The securities are held directly by Bay City Capital LLC (\"BCC LLC\") and represent stock options granted to Carl Goldfischer and transferred to BCC LLC pursuant to an agreement between Dr. Goldfischer and BCC LLC."}],"balance_after":15457,"derivative":{"exercise_price":16,"expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":15457},"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208919,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":16103,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2555},"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208918,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":845008,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":134148},"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208917,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":61378,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9741},"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208916,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":3220915,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":511335},"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208915,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5372,"ownership":{"direct":false,"nature":"(By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":852},"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208914,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":281878,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44749},"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208913,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":13148,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":703380,"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3208912,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":2,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":3,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":4,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T21:08:25.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":690232,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":690232,"source":{"system":"sec-edgar","filing":"0000899243-20-008480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1672619/000089924320008480/doc4.xml","form_type":"4"}},{"id":3209461,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":15457,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests in three equal installments on March 16, 2021, 2022 and 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The securities are held directly by Bay City Capital LLC (\"BCC LLC\") and represent stock options granted to Dr. Goldfischer and transferred to BCC LLC pursuant to an agreement between Dr. Goldfischer and BCC LLC. Dr. Goldfischer disclaims beneficial ownership over the securities owned by BCC LLC except to the extent of his pecuniary interest, if any, in the securities by virtue of his role as managing director of BCC LLC. This report shall not be deemed an admission that the Dr. Goldfischer is the beneficial owner of such shares."}],"balance_after":15457,"derivative":{"exercise_price":16,"expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":15457},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209460,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":16103,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2555},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209459,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":845008,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 16, 2020, the Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":134148},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209458,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":61378,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9741},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209457,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":3220915,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 16, 2020, Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":511335},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209456,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":5372,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":852},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209455,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Preferred Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":281878,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44749},"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209454,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":13148,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by Co-Investment V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":703380,"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3209453,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":78297,"kind":"person","name":"GOLDFISCHER CARL","position":1,"cik":"0001110780","reported_name":"GOLDFISCHER CARL","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":2,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150610,"kind":"organization","name":"Bay City Capital Management V LLC","position":3,"cik":"0001461543","reported_name":"Bay City Capital Management V LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150611,"kind":"organization","name":"Bay City Capital Fund V, L.P.","position":4,"cik":"0001401826","reported_name":"Bay City Capital Fund V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":150612,"kind":"organization","name":"Bay City Capital Fund V Co-Investment Fund, L.P.","position":5,"cik":"0001409813","reported_name":"Bay City Capital Fund V Co-Investment Fund, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T17:12:34.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":690232,"ownership":{"direct":false,"nature":"By entities affiliated with Bay City Capital LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 16, 2020, the Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series Seed Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management V LLC, a Delaware limited liability company (\"Management V\"), Bay City Capital Fund V, L.P., a Delaware limited partnership (\"Fund V\"), and Bay City Capital Fund V Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment V\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management V is the general partner of Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. BCC, the manager of Management V, is also an advisor to Fund V and Co-Investment V and has sole voting and dispositive power with respect to the securities held by Fund V and Co-Investment V. Carl Goldfischer, a Managing Director of BCC, is a member of the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represent securities held by Fund V, including indirect interests of BCC and Management V. BCC and Management V each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":690232,"source":{"system":"sec-edgar","filing":"0000899243-20-008488","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1110780/000089924320008488/doc4.xml","form_type":"4"}},{"id":3342406,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-13T19:18:55.000Z","date":"2019-12-13","kind":"sale","acquired":false,"shares":25320,"price":105.47,"value":2670500.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Co-Investment IV."}],"balance_after":88152,"source":{"system":"sec-edgar","filing":"0000899243-19-029139","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924319029139/doc4.xml","form_type":"4"}},{"id":3342405,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132761,"kind":"organization","name":"Bay City Capital Management IV LLC","position":2,"cik":"0001359070","reported_name":"Bay City Capital Management IV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132762,"kind":"organization","name":"Bay City Capital Fund IV, L.P.","position":3,"cik":"0001360243","reported_name":"Bay City Capital Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":132763,"kind":"organization","name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","position":4,"cik":"0001333817","reported_name":"BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-13T19:18:55.000Z","date":"2019-12-13","kind":"sale","acquired":false,"shares":1174680,"price":105.47,"value":123893499.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Fund IV."}],"balance_after":4089702,"source":{"system":"sec-edgar","filing":"0000899243-19-029139","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000089924319029139/doc4.xml","form_type":"4"}},{"id":3881277,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Redeemable Convertible Preferred Stock","published_at":"2018-06-28T18:22:40.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":472229,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Redeemable Convertible Preferred Stock was convertible into one share of Common Stock at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Redeemable Convertible Preferred Stock was convertible into one share of Common Stock at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Redeemable Convertible Preferred Stock was convertible into one share of Common Stock at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Redeemable Convertible Preferred Stock was convertible into one share of Common Stock at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":472229},"source":{"system":"sec-edgar","filing":"0001179110-18-009105","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000117911018009105/edgar.xml","form_type":"4"}},{"id":3881276,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-28T18:22:40.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":150000,"price":15,"value":2250000.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":622229,"source":{"system":"sec-edgar","filing":"0001179110-18-009105","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000117911018009105/edgar.xml","form_type":"4"}},{"id":3881275,"issuer":{"id":12111,"kind":"organization","name":"Kezar Life Sciences, Inc.","symbol":"KZR"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-28T18:22:40.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":472229,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Redeemable Convertible Preferred Stock was convertible into one share of Common Stock at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein."}],"balance_after":472229,"source":{"system":"sec-edgar","filing":"0001179110-18-009105","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1288452/000117911018009105/edgar.xml","form_type":"4"}},{"id":3897119,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-13T00:50:21.000Z","date":"2018-06-11","kind":"sale","acquired":false,"shares":5908,"price":287.46,"value":1698313.68,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are held by Co-Investment IV."}],"balance_after":113472,"source":{"system":"sec-edgar","filing":"0001179110-18-008424","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000117911018008424/edgar.xml","form_type":"4"}},{"id":3897118,"issuer":{"id":3441,"kind":"organization","name":"MADRIGAL PHARMACEUTICALS, INC.","symbol":"MDGL"},"owners":[{"id":132760,"kind":"organization","name":"BAY CITY CAPITAL LLC","position":1,"cik":"0001288452","reported_name":"BAY CITY CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-13T00:50:21.000Z","date":"2018-06-11","kind":"sale","acquired":false,"shares":274092,"price":287.46,"value":78790486.32,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Bay City Capital LLC, a Delaware limited liability company (\"BCC\"), Bay City Capital Management IV LLC, a Delaware limited liability company (\"Management IV\"), Bay City Capital Fund IV, L.P., a Delaware limited partnership (\"Fund IV\"), and Bay City Capital Fund IV Co-Investment Fund, L.P., a Delaware limited partnership (\"Co-Investment IV\") are deemed to be a \"group\" for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management IV is the general partner of Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV. BCC, the manager of Management IV, is also an advisor to Fund IV and Co-Investment IV and has sole voting and dispositive power with respect to the securities held by Fund IV and Co-Investment IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Fund IV."}],"balance_after":5264382,"source":{"system":"sec-edgar","filing":"0001179110-18-008424","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1157601/000117911018008424/edgar.xml","form_type":"4"}}]}